GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

RYTM · Jun 30, 2026

RHYTHM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001628280-26-052533General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

148.90% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-12.84% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

46.91% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

42.83% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

87.47% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-68.14% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

60.95% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

36.57% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History7 statesHistory building

Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20250/7 normalizedLevel 3 Dec 31, 20250/9 normalizedLevel 3 Mar 31, 20260/8 normalizedLevel 3 Jun 30, 20260/8 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Decreased

Previous: 180.44%
Current: 148.90%
Delta: -31.54%

Cash Generation Increased

Previous: -73.50%
Current: -12.84%
Delta: 60.66%

Growth Decreased

Previous: 83.81%
Current: 46.91%
Delta: -36.89%

Inventory Pressure Decreased

Previous: 47.66%
Current: 42.83%
Delta: -4.83%

Margin Decreased

Previous: 88.09%
Current: 87.47%
Delta: -0.63%

Profitability Increased

Previous: -87.11%
Current: -68.14%
Delta: 18.97%

R And D Intensity Decreased

Previous: 69.41%
Current: 60.95%
Delta: -8.46%

Sbc Intensity Decreased

Previous: 38.43%
Current: 36.57%
Delta: -1.86%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Compared To · Pharmaceutical Preparations peers →Has State · RHYTHM PHARMACEUTICALS, INC. →Transitioned To · RYTM Fundamental State →Transitioned To · RYTM BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · RYTM CASH_GENERATION_INCREASED →Transitioned To · RYTM GROWTH_DECREASED →Transitioned To · RYTM INVENTORY_PRESSURE_DECREASED →Transitioned To · RYTM MARGIN_DECREASED →Transitioned To · RYTM PROFITABILITY_INCREASED →Transitioned To · RYTM R_AND_D_INTENSITY_DECREASED →Transitioned To · RYTM SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.